Connor Clark & Lunn Investment Management Ltd. Acquires 103,405 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 464.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 125,678 shares of the biopharmaceutical company’s stock after purchasing an additional 103,405 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Agios Pharmaceuticals were worth $4,130,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Venturi Wealth Management LLC bought a new stake in Agios Pharmaceuticals in the fourth quarter worth $33,000. Wingate Wealth Advisors Inc. bought a new stake in Agios Pharmaceuticals in the fourth quarter worth $53,000. KBC Group NV lifted its stake in Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 611 shares during the last quarter. Quest Partners LLC lifted its stake in Agios Pharmaceuticals by 139.6% in the third quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 1,283 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in Agios Pharmaceuticals in the third quarter worth $146,000.

Analyst Upgrades and Downgrades

Several analysts have weighed in on AGIO shares. HC Wainwright began coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a “buy” rating and a $58.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Royal Bank of Canada upped their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Scotiabank upped their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Finally, StockNews.com downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Agios Pharmaceuticals has an average rating of “Hold” and an average target price of $56.57.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO opened at $30.93 on Monday. Agios Pharmaceuticals, Inc. has a 1 year low of $27.14 and a 1 year high of $62.58. The company’s 50-day moving average is $33.70 and its 200 day moving average is $41.76. The stock has a market capitalization of $1.77 billion, a P/E ratio of 2.73 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the sale, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.93% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.